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Background: A prospective phase II study was conducted to evaluate the efﬁcacy and toxicity of oral gimatecan in
patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer.
Patients and methods: Patients had a maximum of three prior chemotherapy lines with no more than two prior
platinum-containing regimens and a progression-free interval after the last dose of platinum <12 months. A total dose
of 4 mg/m
2/cycle (0.8 mg/m
2/day from day 1 to day 5) was administered, repeated every 28 days.
Results: From June 2005 to December 2005, 69 assessable patients were enrolled. The best overall response to
study treatment by combined CA-125 and RECIST criteria was partial response in 17 patients (24.6%) and disease
stabilization in 22 patients (31.9%). The median time to progression and overall survival were 3.8 and 16.2 months,
respectively. A total of 312 cycles were administered. Neutropenia grade 4 and thrombocytopenia grade 4 occurred in
17.4% and 7.2% of patients, respectively. Diarrhea grade 4 was never observed. Asthenia and fatigue were reported
by 36.2% and 18.8% of patients, but were all grade 2 or less.
Conclusion: Gimatecan is a new active agent in previously treated ovarian cancer with myelosuppression as main
toxicity.
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introduction
Ovarian cancer is the ﬁfth most frequent cause of cancer death
in women and the leading cause of death from gynecologic
malignancies. The fact that most patients are diagnosed with
advanced-stage disease contributes to a poor 5-year survival of
30%.
Extensive surgical resection followed by platinum-based
combination chemotherapy results in a high initial response
rate, including complete clinically and radiologically conﬁrmed
responses. Even so, a distressingly high percentage of women
with a complete response (CR) experience relapse. Although
there are several active agents for the treatment of women with
relapsed ovarian cancer, there is no predictably curative therapy
for this stage of the disease. In the palliative phase of disease
management, quality of life and the disease- and symptom-free
period are of great importance, as well as the tolerability of the
drugs used. One of the most important factors predictive of
response to therapy for recurrent disease is the interval
following last administration of platinum-based chemotherapy.
Patients who relapse within 6 months are considered to have
resistant disease and have a poorer prognosis, while patients
relapsing later have more sensitive tumors and longer
progression-free and overall survival [1].
Several nonplatinum agents have demonstrated activity in
recurrent disease, such as the topoisomerase II inhibitor
liposomal doxorubicin, the topoisomerase I inhibitor
topotecan, the antimetabolite gemcitabine and trabectedin,
a drug isolated from the marine organism Ecteinascidia
turbinata. However, these drugs have a limited activity, with
a response rate within a narrow range of 10%–30% [2–5].
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(ST1481) is a novel orally active compound belonging to the
camptothecin (CPT) class. It is a potent topoisomerase I
inhibitor, exerting a stronger and more persistent DNA
cleavage than other members of the CPT family. Gimatecan was
highly active in ovarian cancer models. In several experimental
models, gimatecan showed activity in all schedules studied and
a better therapeutic index than the reference CPTs [6].
Pharmacokinetic studies have shown that gimatecan is rapidly
absorbed without a clear linear relationship between dose and
systemic exposure; its half-life is very long, with a mean value of
90 h and, as a consequence, drug plasma accumulation was
observed depending on frequency of dosing. The elimination of
gimatecan is mediated by hepatic and extrahepatic cytochromes
CYP3A4/5 and CYP1A1, respectively. Clinical outcome or side-
effects of gimatecan did not correlate with any pharmacokinetic
parameter (gimatecan investigator’s brochure, data on ﬁle).
A phase I study in patients with solid tumors has been
completed [6]. Gimatecan was administered daily for 5 days for
1 week, 2 weeks or 3 weeks. Thrombocytopenia and
neutropenia were the major dose-limiting toxic effects. The
optimal dose for phase II testing was determined to be 4.0, 5.0
and 5.6 mg/m
2 as total doses for the 1-, 2- and 3-week schedule,
respectively. Six conﬁrmed and peer-reviewed partial responses
(PRs) were observed that lasted from 3.5 to 8.2 months: non-
small-cell lung cancer (2), endometrial (2), cervical (1) and
breast cancer (1). A decrease in CA-125 was observed in one of
two patients with ovarian cancer treated with the 1-week
schedule. On the basis of this, a phase II study of oral gimatecan
in progressing or recurring patients with advanced epithelial
ovarian, fallopian tube or peritoneal cancer, previously treated
with platinum and taxanes, was initiated in Europe.
patients and methods
eligibility
Patients eligible for the study were those with histological diagnosis of
epithelial ovarian, fallopian tube or peritoneal cancer; who had progressing
or recurring disease; had measurable disease according to RECIST criteria
and/or increase in CA-125 [7]; were previously treated with platinum and
taxanes; had a maximum of three prior chemotherapy lines, with no more
than two prior platinum-containing regimens, of which at least one
containing taxanes; had a progression-free interval (PFI) after the last dose
of platinum <12 months; aged ‡18 years; with an Eastern Cooperative
Oncology Group (ECOG) performance status of zero or one and with an
adequate bone marrow, hepatic and renal function. Moreover, all previous
therapies for ovarian cancer had to be discontinued for ‡4 weeks before
study entry and all acute toxic effects (excluding alopecia or peripheral
neuropathy) of any prior therapy had to be recovered; life expectancy had
to be ‡3 months and all patients needed to sign informed consent.
Approval to conduct the study was obtained from the ethical committee
at each participating institution before the start of the trial.
The main reasons for not being eligible for the study were as follows: any
investigational agent received £4 weeks before study entry and/or
concurrent enrollment in another clinical trial; any prior topotecan or
irinotecan treatment or any regimen containing an investigational inhibitor
of topoisomerase I; previous major gastrointestinal surgery or diseases that
could alter gastrointestinal absorption or motility (i.e. active peptic ulcer,
inﬂammatory bowel disease, known intolerance to lactose and
malabsorption syndromes); inability to swallow; any serious cardiac,
infectious, neurological or psychiatric disorders; previous (past 5 years) or
concomitant malignancy at another site; symptomatic brain metastases;
previous treatment with mouse antibodies or previous medication and/or
surgery that would interfere with peritoneum or pleura during the previous
28 days, in patients assessable by CA-125 only [8].
treatment plan and adjustments
Gimatecan was supplied by sigma-tau as oral gelatin capsules. It was
administered orally at a total dose of 4 mg/m
2/cycle (0.8 mg/m
2/day from
day 1 to day 5), repeated every 28 days. The administration was once daily,
in the morning before breakfast. A 1-h post-administration interval was
recommended before any food consumption. Patients were instructed to
swallow each capsule (without chewing them) with water.
In case of hematological toxicity, growth factors were to be used as per the
American Society of Clinical Oncology guidelines [9]. Medications known to
be cytochrome P450 enzymes’ substrates/inducers like enzyme inducing
anticonvulsant drugs and which have shown to increase the clearance of
gimatecan were prohibited during the study. This includes phenytoin,
carbamazepine, phenobarbital, primidone and oxcarbazepine.
The dose was reduced from 4.0 to 3.2 mg/m
2/cycle on the basis of the
worst hematological and non-hematological toxic effects in the previous
cycle. A cycle could be delayed, depending on the type and severity of toxic
effects that occurred during the previous cycle.
study assessments
To be assessable, each patient had to receive at least two treatment cycles,
unless there was unacceptable toxicity, progressive disease (PD) or patients’
request for withdrawal.
Tumor response was the primary efﬁcacy parameter. For patients with
measurable disease, tumor response was assessed every two cycles according to
RECIST criteria [10]. Response status was reviewed by a panel of independent
experts. This assessment of the independent experts was the basis for the
analysis. In patients without measurable disease, the evaluation of response to
therapy was on the basis of changes in CA-125 as per the Gynecologic Cancer
Intergroup criteria [8, 11]. A response was deﬁned as a reduction from the
pretreatment level of CA-125 of at least 50%, conﬁrmed 4 weeks apart.
Secondary efﬁcacy parameters were response duration, time to
progression (TTP) and overall survival.
The qualitative and quantitative toxic effects were graded in agreement
with National Cancer Institute—Common Toxicity Criteria version 2.0.
This included all adverse events (AEs), whether volunteered by the patient,
discovered by questioning or detected through physical examination,
laboratory test or other means.
statistical methods and study design
The trial was carried out according to the Simon’s two-stage optimal
design [12]. The assumptions were as follows: a = 0.05; b = 0.2
(power = 0.80); a level of the true rate of success that would cause an
early refusal of the treatment at stage 1 equal to 5%; a level of the true
rate of success that would cause the acceptance of the treatment in stage
2 equal to 15%. These assumptions required a sample size of 23 patients in
the ﬁrst stage and an additional 33 patients (i.e. 56 patients in total) in the
second one.
After the study drug was tested on 23 assessable patients in the ﬁrst stage,
the trial was to be terminated if one or no patient responded. In the ﬁnal
analysis, if there were at least six responses of 56 assessable patients, it
would be considered that the drug deserved further evaluation.
TTP was calculated from the ﬁrst day of treatment to the date of the ﬁrst
documented tumor progression/recurrence or start of a new antitumor
therapy or death; duration of response was deﬁned as the time between the
date of ﬁrst documented response (i.e. overall response equal to CR or PR)
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antitumor treatment or death and applied only to responding patients;
duration of stable disease (SD) was measured from the ﬁrst day of
treatment to the date of disease progression.
An information was censored in case of death unrelated to the tumor, if
the last visit occurred in nonprogressing patients and in lost-to-follow-up
nonprogressing patients.
Survival [time to death (TTD)] and its 95% conﬁdence interval (CI) were
assessed using Kaplan–Meier methods. Median survival time is presented.
TTD was obtained by computing (date of death 2 date of ﬁrst treatment
administration + 1). Patients alive or lost-to-follow-up are treated as right-
censored information (censoring on last available visit date).
The intention-to-treat (ITT) population was deﬁned as all registered
patients who received at least one dose of study treatment. The efﬁcacy
evaluable (EE) population included all patients who received at least one
dose of the investigational drug, were not major protocol violators, and had
at least one on-study tumor assessment, besides baseline, or experienced
early progression or toxicity.
Patients discontinued from the study that had no other tumor or CA-125
evaluation besides baseline assessment were classiﬁed as ‘PD’ if
discontinued for early progression of the disease; as ‘Unknown’ (and
therefore counted as nonresponders in the primary analysis) if discontinued
for toxicity or were excluded if discontinued for a different reason than
progression and/or toxicity (for example, withdrawal of consent).
Dose intensity was calculated as the weekly rate of therapy per cycle. The
theoretical value was 1 mg/m
2/week.
All statistical analyses were carried out using SAS .
The statistical analysis was carried out by Debioclinic S.A. (Charenton le
Pont, France).
results
patient characteristics
From 20 June 2005 to 21 December 2005, 72 patients were
enrolled in 10 centers. Sixty-nine patients were assessable for
efﬁcacy and safety, while three patients did not receive
treatment because two had a progression of disease (intestinal
occlusion and brain metastases) precluding their inclusion into
the trial and one withdrew her consent before therapy start.
Six patients had minor protocol violations and were included
in the ITT/EE population.
Where appropriate, results are presented by PFI, calculated as
the time elapsing from the last dose of platinum to the start of
any subsequent therapy. The calculation of the interval was
independent whether a nonplatinum regimen was given as last
treatment before gimatecan started. Two PFI intervals were
determined, <6 months or ‡6 months (up to 12 months as per
protocol inclusion criteria), as it is generally accepted that
patients with a PFI <6 months have a less favorable response
rate to chemotherapy.
One patient had a PFI beyond 12 months (13.17 months) but
due to allergy to carboplatinum could not be retreated with
Table 1. Patient baseline characteristics
Statistics PFI
* Overall (N = 69)
<6 months (n = 50) ‡6 months (n = 19)
Age (years) Median 59 65 62
Minimum to maximum 37 to 79 47 to 78 37 to 79
ECOG performance status 0
a, n (%) 37 (74.0) 13 (68.4) 50 (72.5)
1
b, n (%) 12 (24.0) 6 (31.6) 18 (26.1)
ND
c, n (%) 1 (2.0) 0 1 (1.4)
PFI Median (months) 2.32 8.71 3.48
Minimum to maximum 20.07 to 5.98 6.08 to 13.17 20.07 to 13.17
Primary epithelial tumor type
Ovarian n (%) 45 (90.0) 16 (84.2) 61 (88.4)
Peritoneal n (%) 5 (10.0) 3 (15.8) 8 (11.6)
Assessable by RECIST, n (%) Yes 40 (80.0) 14 (73.7) 54 (78.3)
No 10 (20.0) 5 (26.3) 15 (21.7)
Assessable by CA-125, n (%) Yes 41 (82.0) 17 (89.5) 58 (84.1)
No 9 (18.0) 2 (10.5) 11 (15.9)
Number of previous
chemotherapy lines, n (%)
1 9 (18.0) 10 (52.6) 19 (27.6)
2 25 (50.0) 8 (42.1) 33 (47.8)
3 16 (32.0) 1 (5.3) 17 (24.6)
Type of previous
chemotherapy, n (%)
Platinum compounds 50 (100) 19 (100) 69 (100)
Taxanes 50 (100) 19 (100) 69 (100)
Anthracyclines 30 (60.0) 3 (15.8) 33 (47.8)
Other 14 (28.0) 7 (36.8) 21 (30.4)
*PFI (after the last dose of platinum) calculated as time from the last dose of platinum to start of any subsequent therapy and independent whether
a nonplatinum regimen was given as last treatment before gimatecan start.
a0: Able to carry out all normal activity without restriction.
b1: Restricted in physically strenuous activity but ambulatory and able to carry out light work.
cND: Not determined.
PFI, progression-free interval; ECOG, Eastern Cooperative Oncology Group.
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in the PFI ‡6 months group.
The baseline characteristics of the patients are presented in
Table 1.
All patients were Caucasians. There was a predominance of
patients with resistant disease (72.5%), of whom 22% were
refractory, having presented PD (8%) or SD (14%) during
a prior platinum therapy. The main demographic
characteristics were similar between the patients with PFI <6
months and those with PFI ‡6 months.
Most of the patients (72.4%) were pretreated with two or
three prior therapy lines.
Bulky disease (tumor mass >5 cm) was present at baseline in
12 patients (11 with a PFI <6 months and 1 with a PFI ‡6
months).
extent of exposure
A total of 312 cycles was administered with a median of four
cycles per patient (range 1–12). Eight patients stopped
therapy after one cycle only, either because of PD (four
patients) or AE/toxicity (four patients). Twenty-ﬁve patients
(36.2%) were treated with six or more cycles of therapy; of
these patients, 15 had as best response PR and 10 SD.
The achieved median dose intensity was 0.87 mg/m
2/week
(range 0.57–1.00) corresponding to 87% of planned dose-
intensity.
response to treatment
As shown in Table 2, the best overall response to study
treatment by combined CA-125 and RECIST criteria was PR
in approximately one-quarter of the patients overall (17
patients, 24.6%). As expected, response rates were lower in
the short (<6 months) PFI subgroup than in the longer (6–12
months) PFI subgroup. Almost one-third of the patients
had SD, overall as well as per PFI subgroup. PD occurred in
24 patients overall (34.8%), clearly more in the PFI <6
months subgroup (42%) than in the PFI ‡6m o n t h s
subgroup (16%).
Results are quite similar when considering only the patients
assessable by RECIST, as displayed in Table 3. Of the 14
patients who achieved PR, only four had received one prior
therapy line, while seven had received two and the rest three
prior therapy lines. Five patients had liver metastasis (one of
them with bulky disease). All showed responses in liver lesions
with two of them achieving complete disappearance of target
and nontarget liver lesions.
Twelve patients had normalization of CA-125 for at least 4
weeks; nine of them were also assessable by RECIST with six PR
and three SD; the three remaining patients were responders by
CA-125 only. A 50% CA-125 decrease was already observed at
cycle 1 in 14 patients, which was then conﬁrmed at least 4
weeks later.
Drug activity was maintained when results were analyzed by
number of prior therapies or prior use of liposomal doxorubicin
with, respectively, a response rate of 21% (7 of 33 patients) and
29% (5 of 17 patients) when gimatecan was given as third or
fourth therapy line and 17% (4 of 23 patients) or 50% (5 of 10
patients) when gimatecan was administered after a prior
liposomal doxorubicin given as second or third therapy line.
Table 4 summarizes the median TTP, response duration and
SD duration (CR/PR/SD as best response).
Time to response ranged between 26 days and 113 days, with
a median value of 56 days.
Survival results are shown in Figure 1 for the subgroups with
PFI <6 and ‡6 months. Median overall survival time was 16.2
months (95% CI 11.2–19.0). Median survival time was longer,
as expected, in the PFI ‡6 months subgroup, being 23.3
months, while the time observed in the PFI <6 months
subgroup was 12.4 months.
toxicity
All patients included experienced at least one AE, with a mean
of 4.5 AEs per patient. Unsuspected and suspected AEs were
reported in 81.2% and 95.7% of patients, respectively. Table 5
lists the suspected grade 3 and grade 4 AEs as well as the
suspected AEs reported in >15% of patients.
The majority of suspected AEs were gastrointestinal toxic
effects affecting 82.6% of patients. Grade 3 diarrhea was
Table 2. Summary of best overall response by combined CA-125 and/or
RECIST criteria, ﬁnal assessment after radiology expert’s review (ITT/EE
population)
Best response after
radiology expert’s review
PFI (N = 69) Overall (N = 69)
<6
months
(n = 50)
‡6
months
(n = 19)
Best overall response
a
CR, n (%) 0 0 0
PR, n (%) 8 (16.0) 9 (47.4) 17 (24.6)
SD, n (%) 16 (32.0) 6 (31.6) 22 (31.9)
PD, n (%) 21 (42.0) 3 (15.8) 24 (34.8)
UK, n (%) 5 (10.0) 1 (5.3) 6 (8.7)
Response rate
CR + PR, n (%) 8 (16.0) 9 (47.4) 17 (24.6)
aBest overall response is the combined analysis of CA-125/RECIST criteria
in the assessment of all target/nontarget lesions.
ITT, intention-to-treat; EE, efﬁcacy evaluable; PFI, progression-free
interval; CR, complete response, PR, partial response; SD, stable disease;
PD, progressive disease; UK, unknown.
Table 3. Best overall response by RECIST criteria after radiology expert’s
review (ITT/EE population)
Investigator
and/or
expert assessment
PFI (N = 54) Overall response
(N = 54) <6
months
(n = 40)
‡6
months
(n = 14)
CR, n (%) 0 0 0
PR, n (%) 7 (17.5) 7 (50.0) 14 (25.9)
SD, n (%) 11 (27.5) 4 (28.6) 15 (27.8)
PD, n (%) 15 (37.5) 3 (21.4) 18 (33.3)
UK, n (%) 7 (17.5) 0 7 (13.0)
ITT, intention-to-treat; EE, efﬁcacy evaluable; PFI, progression-free
interval; CR, complete response, PR, partial response; SD, stable disease;
PD, progressive disease; UK, unknown.
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recorded. A withdrawal from the study was observed in 4.3% of
patients for nausea and in 2.9% for vomiting.
ThesecondmostfrequentAEsweremyelosuppression(69.6%
of patients), leading to complications (febrile neutropenia) only
in 2.9% of cases. A withdrawal from the study was observed in
5.8% of patients for thrombocytopenia, in 2.9% for neutropenia
and in one for febrile neutropenia (1.4%).
The third most frequently observed suspected AEs were
asthenia (36.2% of patients) and fatigue (18.8% of patients), but
these were all considered mild to moderate (grade 2 or less).
No drug-related deaths occurred. Most of the deaths during
the study were due to disease progression.
Dose reductions due to neutropenia or thrombocytopenia
occurred in 11 (16%) patients, while dose delays for
hematological toxicity were recorded in 28 patients (41%).
Treatment with growth factors during the study period
involved 25 patients (36%) and 58 of 312 (18.6%) cycles
administered. Twelve patients (17.4%) required transfusion
with either red blood cells (11.6%) or platelets (10.1%).
Hemoglobin, neutrophils and platelets decreases were the
most frequent hematological abnormalities. The median nadir
for neutrophils was 1.65 · 10
9/L (range 0.01–8.17) and for
platelets was 141 · 10
9/L (range 2–457). The median time to
nadir for these parameters was 22 days at cycle 1 and 20 to 22
days when all cycles of treatment are considered.
The ECOG performance status was zero in almost three-
quarters of the patients (73%) at baseline, in 69% of patients at
cycle 1 and in 63% of patients at the end of the last cycle. The
proportion of patients with ECOG performance status of one
remained practically constant at baseline, cycle 1 or last cycle.
discussion
Our study showed that gimatecan is an active drug in patients
with epithelial ovarian, fallopian tube or peritoneal cancer,
progressing or recurring during or after prior treatment with
platinum compounds and taxanes and whether or not
previously treated by anthracyclines. An overall response of
16% in patients with PFI <6 months and 47.4% in those with
PFI ‡6 months was found by combining CA-125 and
RECIST criteria and assessed by an independent radiology
expert’s review. These responses were obtained after a
median of 56 days and were maintained for a median of 7.6
months in the cohort of patients with PFI <6 months and 6.9
months for those with a PFI ‡6 months, while median TTP
in both cohorts were 2.9 months and 6.3 months,
respectively. These results were obtained at the cost of
manageable toxicity.
Activity as expressed by a PR by CA-125 and/or RECIST
criteria was three times higher in the subgroup of patients with
PFI ‡6 months compared with those with a PFI <6 months
(47.4% versus 16%). Similarly, the proportion of patients with
PR or disease stabilization was much higher among patients
with a PFI ‡6 months (78% versus 48%). Among the patients
who showed a decrease in CA-125, almost half achieved
a marker normalization.
As expected, the proportion of responders was very much
inﬂuenced by the interval after platinum therapy, being more
clear-cut in the subgroup of patients with PFI ‡6 months versus
those with PFI <6 months.
Interestingly, the duration of response was independent from
the PFI, being of at least 6 months in almost 73% and 75% of
Table 4. TTP, response duration and SD duration
PFI (N = 69) Overall
<6 months ‡6 months
Median TTP (months) (95% CI) 2.9 (2.0–3.9) (n = 50) 6.3 (4.6–8.3) (n = 19) 3.8 (2.8–5.7) (N = 69)
Median time with CR/PR (months) (95% CI) 7.6 (3.6–9.9) (n = 8) 6.9 (5.7–NR) (n = 9) 7.6 (6.2–9.9) (n = 17)
Median time with SD (months) (95% CI) 5.9 (4.0–6.9) (n = 24) 7.4 (5.1–12.2) (n = 15) 6.3 (5.7–7.2) (n = 39)
TTP, time to progression; SD, stable disease; PFI, progression-free interval; CI, conﬁdence interval, CR, complete response, PR, partial response,N R ,n o tr e a c h e d .
Figure 1. Kaplan–Meier survival curves by progression-free interval (PFI).
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respectively. However, SD duration was longer among patients
with PFI ‡6 months (7.4 versus 5.9 months, respectively).
Correspondingly, the median TTP was longer for the subgroup
with PFI ‡6 months.
The median survival of 1 year observed in the PFI <6 months
subgroup seems interesting, especially considering that 82% of
this population had received at least two or three prior
chemotherapy regimens and that 22% of these patients were
refractory (presenting PD or SD) to a prior platinum therapy.
The median survival of 2 years in the PFI >6 months subgroup
is also interesting for a future development of the product in
this indication.
The durable responses and disease stabilization observed in
the study could potentially transform in a clinical beneﬁt for
the patients.
All patients were included in the analysis of safety. A number
of cycles equal or greater than six was administered in 25
patients (36.2%), and all together 312 cycles were delivered,
showing that the oral therapy with gimatecan was well
tolerated. The lack of an evident ECOG performance status
deterioration during treatment seems to conﬁrm the good
safety proﬁle of gimatecan.
At least one dose reduction or dose delay were observed in
31.9% or 59.4% of patients, respectively. Hematological
toxicity, mainly neutropenia, was the most frequent reason for
dose reduction in 16% of patients, and for dose delay in 41%.
Despite dose reduction or delays, a rather high-dose intensity
could be maintained during the study, with a median value of
0.87 mg/m
2/week versus a theoretical value of 1 mg/m
2/week.
Growth factor use affected 18.6% of cycles.
The main toxicity was myelosuppression (neutropenia and
thrombocytopenia). However, the incidence of febrile
neutropenia was quite low (two patients, 2.9%), one patient
interrupted treatment because of this event and the other had
dose reduced to 3.2 mg/m
2.
Although the AEs reported in this study were those expected
with this therapeutic class, there seems to be a low incidence of
myelosuppression and diarrhea grade 3 and 4. Neutropenia
grade 4 occurred in 17.4% of patients treated with gimatecan,
while it is reported in 77% of patients receiving topotecan. The
rate of grade 4 neutropenia with fever/infection was 1.4% in
this study and may be as high as 23% in patients receiving
topotecan [13].
Diarrhea grade 4 was never observed with gimatecan, while
grade 4 late diarrhea occurred in 10% of irinotecan-treated
patients [14]. The presence of diarrhea never caused treatment
interruption. Gastrointestinal AEs such as nausea and
vomiting were overall manageable, never precluding therapy
administration except in one case. Gimatecan did not
produce hepatotoxicity or sensory neuropathy, which are
observed with, respectively, trabectedin and the new
epothilones [5, 15, 16].
These observations are particularly relevant since 42% of
patients in this study were elderly, and 72.4% had received two
or three prior therapy lines, making them more likely to present
enhanced toxicity related to myelosuppression.
With the limitation that interpretation of activity and
safety from this trial is not on the basis of comparative
data, the conclusion that may be driven is that gimatecan
has shown to be active in previously treated ovarian cancer,
with a manageable safety proﬁle. The high proportion of
patients who achieve durable responses and disease
stabilization, together with the lack of deterioration of
performance status and the observed tolerability proﬁle,
with myelosuppression as main toxicity, may justify
further evaluations of this new oral drug in the proposed
indication.
Table 5. Most relevant suspected AEs by worst NCI-CTC grade
System organ class preferred
term
Safety population (N = 69)
Grade 1, n (%) Grade 2, n (%) Grade 3, n (%) Grade 4, n (%) Total, n (%)
Anemia 7 (10.1) 21 (30.4) 6 (8.7) 3 (4.3) 37 (53.6)
Febrile neutropenia 0 0 1 (1.4) 1 (1.4) 2 (2.9)
Leukopenia 3 (4.3) 10 (14.5) 9 (13.0) 4 (5.8) 26 (37.7)
Neutropenia 1 (1.4) 9 (13.0) 14 (20.3) 12 (17.4) 36 (52.2)
Thrombocytopenia 9 (13.0) 6 (8.7) 10 (14.5) 5 (7.2) 30 (43.5)
Constipation 8 (11.6) 6 (8.7) 0 0 14 (20.3)
Diarrhea 13 (18.8) 8 (11.6) 4 (5.8) 0 25 (36.2)
Nausea 25 (36.2) 22 (31.9) 1 (1.4) 0 48 (69.6)
Vomiting 25 (36.2) 9 (13.0) 2 (2.9) 0 36 (52.2)
Abdominal pain upper 3 (4.3) 5 (7.2) 1 (1.4) 0 9 (13)
Asthenia 8 (11.6) 17 (24.6) 0 0 25 (36.2)
Fatigue 10 (14.5) 3 (4.3) 0 0 13 (18.8)
Anorexia 9 (13.0) 3 (4.3) 0 0 12 (17.4)
Bone pain 0 0 1 (1.4) 0 1 (1.4)
Osteonecrosis 0 0 0 1 (1.4) 1 (1.4)
Epistaxis 2 (2.9) 0 1 (1.4) 0 3 (4.3)
Alopecia 8 (11.6) 4 (5.8) 0 0 12 (17.4)
AEs, adverse events; NCI CTC, National Cancer Institute Common—Toxicity Criteria.
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